Estimating the Survival Rate in Glioblastoma Multiforme Patients who Received a Peptide Vaccine: A Systematic Review and Meta-analysis.

IF 3 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current drug targets Pub Date : 2023-01-01 DOI:10.2174/1389450124666230816114131

Masoumeh Eliyasi Dashtaki, Zahra Moradi, Yousef Moradi, Elham Asadi, Sorayya Ghasemi

{"title":"Estimating the Survival Rate in Glioblastoma Multiforme Patients who Received a Peptide Vaccine: A Systematic Review and Meta-analysis.","authors":"Masoumeh Eliyasi Dashtaki, Zahra Moradi, Yousef Moradi, Elham Asadi, Sorayya Ghasemi","doi":"10.2174/1389450124666230816114131","DOIUrl":null,"url":null,"abstract":"Introduction: Glioblastoma Multiforme (GBM) has a poor prognosis, with current treatments providing no advantage in terms of survival. Certain new immunotherapy methods, such as peptide vaccines, have been used in clinical trials. In this meta-analysis, the effectiveness of peptide vaccinations on the survival rate of GBM patients was studied.Methods: A comprehensive search was carried out using three electronic databases: PubMed, Scopus, and ISI. The purpose of this research was to assess Overall Survival (OS). The pooled overall one-year and two-year survival rates in GBM with peptide vaccination were calculated using the general inverse variance technique as random effects hazard ratios (HRs). In the study, subgroups of countries were compared with each other. Japan had the highest one-year survival rate, and the US had the highest two-year survival rate.Results: With 95% Confidence Intervals (CIs), the one-year OS rate in GBM patients treated with peptide vaccination increased significantly, but the two-year survival rate did not increase. As a result, while additional research is needed, it cannot be concluded that it is an effective therapy for GBM.Conclusion: Our study found that while peptide vaccination treatment did not increase second-year survival, it improved first-year survival. More research needs to be done to find effective vaccinebased treatments for GBM that can help patients survive longer.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"998-1007"},"PeriodicalIF":3.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1389450124666230816114131","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Glioblastoma Multiforme (GBM) has a poor prognosis, with current treatments providing no advantage in terms of survival. Certain new immunotherapy methods, such as peptide vaccines, have been used in clinical trials. In this meta-analysis, the effectiveness of peptide vaccinations on the survival rate of GBM patients was studied.

Methods: A comprehensive search was carried out using three electronic databases: PubMed, Scopus, and ISI. The purpose of this research was to assess Overall Survival (OS). The pooled overall one-year and two-year survival rates in GBM with peptide vaccination were calculated using the general inverse variance technique as random effects hazard ratios (HRs). In the study, subgroups of countries were compared with each other. Japan had the highest one-year survival rate, and the US had the highest two-year survival rate.

Results: With 95% Confidence Intervals (CIs), the one-year OS rate in GBM patients treated with peptide vaccination increased significantly, but the two-year survival rate did not increase. As a result, while additional research is needed, it cannot be concluded that it is an effective therapy for GBM.

Conclusion: Our study found that while peptide vaccination treatment did not increase second-year survival, it improved first-year survival. More research needs to be done to find effective vaccinebased treatments for GBM that can help patients survive longer.

查看原文本刊更多论文

评估接受肽疫苗的多型胶质母细胞瘤患者的生存率：系统综述和荟萃分析。

简介：多型胶质母细胞瘤（GBM）预后不佳，目前的治疗方法在生存方面没有优势。某些新的免疫疗法方法，如肽疫苗，已被用于临床试验。在这项荟萃分析中，研究了肽疫苗对GBM患者生存率的有效性。方法：使用PubMed、Scopus和ISI三个电子数据库进行综合检索。本研究的目的是评估总体生存率（OS）。使用通用逆方差技术计算肽疫苗接种GBM的一年和两年总生存率，作为随机效应危险比（HR）。在这项研究中，对国家的亚组进行了相互比较。日本的一年生存率最高，美国的两年生存率最高。结果：在95%置信区间（CI）下，接受肽疫苗接种的GBM患者的一年OS率显著提高，但两年生存率没有提高。因此，虽然还需要更多的研究，但不能得出结论认为它是GBM的有效治疗方法。结论：我们的研究发现，虽然肽疫苗接种治疗没有增加第二年的生存率，但它提高了第一年的生存期。需要进行更多的研究，以找到有效的基于疫苗的GBM治疗方法，帮助患者存活更长时间。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug targets 医学-药学

CiteScore

6.20

自引率

0.00%

发文量

127

审稿时长

3-8 weeks

期刊介绍： Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.